ENTPD1 and cholangiocarcinoma: CD39 and CD73 have been identified as being overexpressed in various tumor cells, including those from gastric cancer, ovarian cancer, cholangiocarcinoma, lung cancer, and bladder cancer [24–27, 75, 76].